Skip to content
Open access

Somatic Evolution of a Germline Antibody Expands its Breadth to Neutralize Early SARS‐CoV‐2 Omicron Variants

Jul 2026 · Advancement of science · 0 citations · 58 references
Medicine

TL;DR

The structural basis by which specific mutations enhance cross‐variant recognition of SARS‐CoV‐2 is defined, highlighting the underappreciated breadth encoded within the naïve B‐cell repertoire and providing a conceptual framework for engineering and eliciting antibody responses resilient to future antigenic drift.

Abstract

ABSTRACT Rapid antigenic drift of the SARS‐CoV‐2 receptor‐binding domain (RBD) underlies immune escape and continues to challenge the durability of antibody‐mediated protection. Among the major classes of RBD‐directed antibodies, germline‐encoded IGHV3‐53 responses are highly potent against early SARS‐CoV‐2 variants but are generally compromised by Omicron‐associated mutations. Here, we identify an intrinsically cross‐reactive IGHV3‐53 germline antibody that recognizes multiple pre‐Omicron variants, including SARS‐CoV‐2 wild‐type, Alpha, and Delta. Notably, we demonstrate that targeted somatic evolution can further expand this breadth to overcome the immune escape of different Omicron variants. Guided by integrated structural and sequence analyses, we introduce four somatic mutations (G26E, T28I, S53P, and Y58F) into the germline antibody, resulting in markedly enhanced binding and neutralization of Omicron BA.1, and BA.4/5. High‐resolution crystal structures reveal that these mutations re‐establish interactions disrupted by substitutions in the Omicron RBD and improve binding at a remodeled epitope interface. Collectively, our findings define the structural basis by which specific mutations enhance cross‐variant recognition of SARS‐CoV‐2. This work highlights the underappreciated breadth encoded within the naïve B‐cell repertoire and provides a conceptual framework for engineering and eliciting antibody responses resilient to future antigenic drift.

Read PDF

Similar papers

Open access Sep 2026

Somatic Hypermutations Enhance Neutralization Breadth of IGHV3‐53/3‐66 Public Antibodies Against SARS‐CoV‐2 Variants

This work assessed whether non‐broadly neutralizing IGHV3‐53/3‐66 antibodies could mature into broadly neutralizing antibodies and found some acquire broad neutralizing activity through accumulation of somatic hypermutations.

Takeo Kuwata, K. Okazaki, Hiroshi Morioka et al. · 0 citations
Open access Aug 2026

Structural and mutational analyses define distinct molecular routes to broad SARS-CoV-2 receptor-binding domain recognition

Two human-derived monoclonal antibodies are characterized that recognize conserved epitopes on the SARS-CoV-2 RBD and retain activity across antigenically distinct variants, and conserved, mutationally constrained epitopes may serve as targets for vaccines designed to elicit antibody responses resilient to ongoing SARS...

M. Abernathy, William B. Foreman, Jasmyn A. Lopez et al. · 0 citations
Open access Aug 2026

SARS‐CoV‐2 Neutralization Breadth Is Shaped by Variant Exposure and Immune History

Findings demonstrate that both the nature and number of antigenic exposures can shape the potency and breadth of SARS‐CoV‐2 neutralizing responses, emphasizing the need for continued variant monitoring and periodic vaccine reformulation to maintain population‐level protection.

Greta Vizgirda, Alexander P. Underwood, Ulrik Fahnøe et al. · 0 citations
Open access Sep 2026

An Engineered HR1‐Stem Helix‐HR2 Trimeric Platform for Developing Broad‐Spectrum Coronavirus Vaccines

RHS is established as a generalizable strategy for overcoming viral immune evasion and advancing next‐generation vaccine design, and is readily adaptable to antigens from SARS‐CoV and MERS‐CoV, underscoring its versatility for pan‐coronavirus vaccine development.

Xi-Kui Sun, Junhao Fan, Xiaolu Xie et al. · 0 citations
Open access Aug 2026

A structural and mechanistic atlas of NTD antibody neutralization and immune escape across SARS-CoV-2 prototype and its (sub-)variants.

Mechanistic studies reveal that NTD-5 and NTD-9 antibodies neutralize by inducing S1 shedding, thereby extending this mechanism to selected NTD-directed antibodies and providing a structural and mechanistic framework for rational vaccine and antibody design resilient to antigenic drift.

Jian-Jie Zhou, Wen-Yu Li, Xiaoyu Wang et al. · 0 citations
Open access Aug 2026

Serum Escape Landscape of SARS-CoV-2 Omicron JN.1 and XEC RBD Under COVID-19 Vaccine Breakthrough Immunity in China

The findings suggest that SARS-CoV-2 antigenic evolution follows the pattern of multiple pathways within a constrained space, providing new insights into the adaptive mechanisms of Omicron-derived variants under hybrid immune pressure.

Cheng-Wei Shao, Jian-Guang Fu, Fei Deng et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.